This company listing is no longer active
Spectrum Pharmaceuticals Future Growth
Future criteria checks 5/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Spectrum Pharmaceuticals.
Key information
67.3%
Earnings growth rate
75.4%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 35.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 25 Jul 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 201 | 97 | 36 | 141 | 4 |
| 12/31/2024 | 127 | 14 | 18 | 36 | 5 |
| 12/31/2023 | 73 | -18 | -21 | 2 | 3 |
| 3/31/2023 | 26 | -68 | -88 | -88 | N/A |
| 12/31/2022 | 10 | -78 | -97 | -97 | N/A |
| 9/30/2022 | N/A | -106 | -102 | -102 | N/A |
| 6/30/2022 | N/A | -117 | -109 | -109 | N/A |
| 3/31/2022 | N/A | -138 | -115 | -115 | N/A |
| 12/31/2021 | N/A | -158 | -120 | -119 | N/A |
| 9/30/2021 | N/A | -169 | -121 | -122 | N/A |
| 6/30/2021 | N/A | -184 | -127 | -125 | N/A |
| 3/31/2021 | N/A | -166 | -127 | -123 | N/A |
| 12/31/2020 | N/A | -171 | -127 | -122 | N/A |
| 9/30/2020 | N/A | -162 | -127 | -120 | N/A |
| 6/30/2020 | N/A | -140 | -131 | -119 | N/A |
| 3/31/2020 | N/A | -136 | -138 | -128 | N/A |
| 12/31/2019 | N/A | -135 | -144 | -135 | N/A |
| 9/30/2019 | N/A | -148 | -127 | -116 | N/A |
| 6/30/2019 | N/A | -191 | -103 | -100 | N/A |
| 3/31/2019 | N/A | -147 | -79 | -76 | N/A |
| 12/31/2018 | N/A | -127 | -65 | -62 | N/A |
| 9/30/2018 | 29 | -102 | -63 | -63 | N/A |
| 6/30/2018 | 65 | -51 | -59 | -59 | N/A |
| 3/31/2018 | 99 | -87 | -46 | -45 | N/A |
| 12/31/2017 | N/A | -101 | -39 | -39 | N/A |
| 9/30/2017 | 135 | -81 | -30 | -29 | N/A |
| 6/30/2017 | 132 | -81 | -36 | -36 | N/A |
| 3/31/2017 | 132 | -84 | -54 | -54 | N/A |
| 12/31/2016 | 146 | -70 | N/A | -40 | N/A |
| 9/30/2016 | 162 | -55 | N/A | -34 | N/A |
| 6/30/2016 | 157 | -56 | N/A | -30 | N/A |
| 3/31/2016 | 168 | -35 | N/A | 5 | N/A |
| 12/31/2015 | 163 | -53 | N/A | 7 | N/A |
| 9/30/2015 | 164 | -50 | N/A | 15 | N/A |
| 6/30/2015 | 183 | -42 | N/A | 34 | N/A |
| 3/31/2015 | 185 | -44 | N/A | 31 | N/A |
| 12/31/2014 | 187 | -46 | N/A | -4 | N/A |
| 9/30/2014 | 176 | -82 | N/A | -7 | N/A |
| 6/30/2014 | 171 | -78 | N/A | -30 | N/A |
| 3/31/2014 | 157 | -84 | N/A | -64 | N/A |
| 12/31/2013 | 156 | -62 | N/A | -2 | N/A |
| 9/30/2013 | 184 | -15 | N/A | -2 | N/A |
| 6/30/2013 | 211 | 14 | N/A | 30 | N/A |
| 3/31/2013 | 247 | 42 | N/A | 67 | N/A |
| 12/31/2012 | 268 | 94 | N/A | 72 | N/A |
| 9/30/2012 | 251 | 95 | N/A | 75 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: NTR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NTR is expected to become profitable in the next 3 years.
Revenue vs Market: NTR's revenue (35.5% per year) is forecast to grow faster than the German market (3.6% per year).
High Growth Revenue: NTR's revenue (35.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NTR's Return on Equity is forecast to be high in 3 years time